CLINICAL TRIALS PROFILE FOR IMODIUM A-D EZ CHEWS
✉ Email this page to a colleague
All Clinical Trials for IMODIUM A-D EZ CHEWS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00075868 ↗ | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer | Completed | National Cancer Institute (NCI) | Phase 3 | 2003-12-01 | RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. |
| NCT00075868 ↗ | Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer | Completed | Radiation Therapy Oncology Group | Phase 3 | 2003-12-01 | RATIONALE: Octreotide may be effective in preventing or controlling diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. It is not yet known whether octreotide is effective in treating diarrhea. PURPOSE: This randomized phase III trial is studying octreotide in preventing or reducing diarrhea in patients who are undergoing chemoradiotherapy for anal or rectal cancer. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | Bausch Health Americas, Inc. | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | Valeant Pharmaceuticals International, Inc. | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00292344 ↗ | Rifaximin, Loperamide and the Combination to Treat Travelers' Diarrhea | Completed | The University of Texas Health Science Center, Houston | Phase 4 | 2004-06-01 | Most cases of travelers' diarrhea are caused by bacterial pathogens which respond slowly to antibiotic treatment.The study was designed to determine the value of rapidly acting loperamide (imodium) combined with curative dose of the poorly absorbed rifaximin in travelers' diarreha treatment. |
| NCT00360828 ↗ | Phase II Study of Irinotecan HCI for Recurrent Anaplastic Astrocytomas, Mixed Malignant Gliomas, and Oligodendrogliomas | Terminated | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 | 2006-02-01 | Phase 2 trial to explore the efficacy and safety of irinotecan (CPT-11). Also administered at each cycle was zofran/Kytril/Anzemet, decadron, and IV atropine. At each cycle, patient exams and interviews as well as lab results were to help the research team to determine the symptomatic side effects of the treatment. Recorded past toxicities were to be compared with current side effects. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for IMODIUM A-D EZ CHEWS
Condition Name
Clinical Trial Locations for IMODIUM A-D EZ CHEWS
Trials by Country
Clinical Trial Progress for IMODIUM A-D EZ CHEWS
Clinical Trial Phase
Clinical Trial Sponsors for IMODIUM A-D EZ CHEWS
Sponsor Name
